There is something that has been eating at me and
Post# of 30028
(Total Views: 723)
Posted On: 02/07/2020 11:50:29 AM
There is something that has been eating at me and I don't know the answer. I know there are some people with heavy scientific backgrounds here that read or did read the board, so if you're still around; any thoughts on this...
Eltoprazine has been tested and was being developed/used in pill format.
It is stable and able to cross the BBB in that formulation.
CBD is also able to cross that in many different formulations.
One such form is OraPatch™, a patented oral delivery method for various substances including caffeine and cannabidiol (“CBD”) from PetVivo Holdings, Inc. (OTC
ETV) (“PetVivo”).
The patented oral adhesion technology, OraPatch™, is a slowly degradable protein wafer-disc that attaches to and assimilates with the mouth’s inner lining. PetVivo is the holder of patents for this unique and cutting-edge method for nutraceutical and supplement delivery.
https://www.emerald-organic.com/press-release...ldings-inc
So, if both can pass the BBB, they must share "some" similar pharmacokinetics / pharmadynamics. I just am wondering if ELTOP could be formulated to the same type of delivery system.
What got me thinking of that was the granting of Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease.
"Once issued, the patent will protect the use of eltoprazine in the treatment of Parkinson’s and PD-LID through 2034. Elto Pharma is focused on the development of eltoprazine as an oral formulation for the treatment of PD-LID, Adult ADHD and Agitation in Alzheimer’s disease."
https://www.amarantus.com/news/press-releases...-notice-of
That would be quite a game changer and a massive level up if that is a possibility.
I imagine still a far way off if there is even a chance, but I like the idea and if anyone can expound on this I would love to hear some feedback / input.
All speculation on my part....
Much Aloha
Eltoprazine has been tested and was being developed/used in pill format.
It is stable and able to cross the BBB in that formulation.
CBD is also able to cross that in many different formulations.
One such form is OraPatch™, a patented oral delivery method for various substances including caffeine and cannabidiol (“CBD”) from PetVivo Holdings, Inc. (OTC
ETV) (“PetVivo”). The patented oral adhesion technology, OraPatch™, is a slowly degradable protein wafer-disc that attaches to and assimilates with the mouth’s inner lining. PetVivo is the holder of patents for this unique and cutting-edge method for nutraceutical and supplement delivery.
https://www.emerald-organic.com/press-release...ldings-inc
So, if both can pass the BBB, they must share "some" similar pharmacokinetics / pharmadynamics. I just am wondering if ELTOP could be formulated to the same type of delivery system.
What got me thinking of that was the granting of Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease.
"Once issued, the patent will protect the use of eltoprazine in the treatment of Parkinson’s and PD-LID through 2034. Elto Pharma is focused on the development of eltoprazine as an oral formulation for the treatment of PD-LID, Adult ADHD and Agitation in Alzheimer’s disease."
https://www.amarantus.com/news/press-releases...-notice-of
That would be quite a game changer and a massive level up if that is a possibility.
I imagine still a far way off if there is even a chance, but I like the idea and if anyone can expound on this I would love to hear some feedback / input.
All speculation on my part....
Much Aloha
(1)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼